<p>隨着全球市場應對地緣政治緊張局勢和貨幣政策變化的複雜性，美國股市展現出韌性，主要指數在鷹派的美聯儲立場和波動的油價背景下仍然錄得上漲。在這種情況下，識別高增長科技股需要關注那些在人工智能等領域展現出強勁盈利潛力和創新能力的公司，這些公司有望從當前市場動態中受益。</p>
<h3>全球十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 197 只股票的完整列表。</p>
<p>在這裏，我們突出顯示了篩選器中我們首選股票的一個子集。</p>
<h2>Pharming Group (ENXTAM:PHARM)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Pharming Group N.V. 是一家生物製藥公司，專注於開發和商業化針對罕見疾病的蛋白質替代療法和精準醫療，業務覆蓋美國、歐洲及國際市場，市值為 10.1 億歐元。</p>
<p><strong>運營：</strong> Pharming Group 的收入主要來自其產品 Joenja® 和 Ruconest®，分別貢獻 5821 萬美元和 3.1792 億美元。該公司專注於生物製藥領域，致力於罕見疾病，市值約為 10 億歐元。</p>
<p>Pharming Group 最近的進展和財務增長反映了其在生物技術領域的潛力，特別是其針對 APDS 的開創性治療 Joenja。該公司報告顯示，年度收入從前一年的 2.972 億美元上升至 3.7613 億美元，淨虧損從 1184 萬美元轉變為淨利潤 285 萬美元。這一復甦得益於戰略性會議展示和積極的臨牀試驗結果，增強了其在歐洲和日本的市場存在。預計每年盈利增長為 36.7%，研發專注於通過創新治療解決罕見疾病，Pharming 正在將自己定位為專業醫療解決方案的關鍵參與者。</p>
<ul>
<li>解鎖我們對 Pharming Group 股票分析的全面見解，詳見此健康報告。</li>
<li>通過查看我們的歷史報告瞭解 Pharming Group 的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 5 月 ENXTAM:PHARM 收入和支出明細</p>
<h2>CELSYS (TSE:3663)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> CELSYS, Inc. 在日本運營，提供內容創作解決方案，市值約為 398.5 億日元。</p>
<p><strong>運營：</strong> 該公司專注於在日本提供內容創作解決方案，主要通過軟件銷售和相關服務產生收入，特別強調數字插圖和動畫工具。</p>
<p>CELSYS 在其財務運營中展現出韌性和戰略前瞻性，尤其體現在其最近的企業行動中，以優化庫藏股。預計年盈利增長為 22.3%，收入年增長率為 9.7%，顯著超過日本市場的平均水平。這些數據得益於強勁的研發投資，不僅突顯了 CELSYS 對創新的承諾，還與行業向更先進數字解決方案的趨勢相一致。最近的股息調整反映了對股東回報的戰術性方法，在增長再投資和通過預計從每股 14.00 日元提高到 20.00 日元的股息直接提升股東價值之間取得平衡。</p>
<ul>
<li>點擊這裏深入瞭解 CELSYS 的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 CELSYS 過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月 TSE:3663 盈利和收入增長</p>
<h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Plus Alpha Consulting Co., Ltd. 在日本提供市場營銷和人力資源解決方案，市值為 923.3 億日元。</p>
<p><strong>運營：</strong> Plus Alpha Consulting Co., Ltd. 主要通過其人力資源解決方案產生收入，貢獻 138.4 億日元，以及市場營銷解決方案，貢獻 37.9 億日元。該公司專注於日本市場，致力於這兩個關鍵領域推動其業務運營。</p>
<p>Plus Alpha ConsultingLtd 最近展現出強勁的財務表現，季度銷售額從 38.9 億日元增加到 44.4 億日元，淨收入從 7.5555 億日元激增至 11.5 億日元，同比大幅增長。這一增長軌跡得益於 12.5% 的年收入增長率，顯著超過日本市場的平均水平 6%。該公司對創新的承諾體現在其研發支出趨勢上，與行業向更復雜數字解決方案的轉變相一致，確保在不斷發展的科技領域中的競爭力。</p>
<ul>
<li>點擊探索 Plus Alpha ConsultingLtd 健康報告中我們發現的詳細信息。</li>
<li>瞭解 Plus Alpha ConsultingLtd 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown"/></p>
<p>TSE:4071 收入和支出明細截至 2026 年 5 月</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接深入瞭解我們全球高增長科技和人工智能股票篩選器中的 197 家公司。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>使用免費的 Simply Wall St 應用程序更智能地投資，提供全球每個股票市場的詳細見解。</li>
</ul>
<h2>準備好不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新警告信號或風險的提醒</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

全球科技股指數 ETF - iShares

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

<p>隨着全球市場面臨地緣政治緊張局勢和貨幣政策變化，美國股票依然表現出韌性。高增長的科技股備受關注，尤其是在人工智能等領域。值得注意的公司包括 Pharming Group、CELSYS 和 Plus Alpha Consulting，它們各自在收入和盈利增長方面表現強勁。Pharming Group 報告收入增長至 3.7613 億美元，淨利潤為 285 萬美元，而 CELSYS 和 Plus Alpha Consulting 在各自市場上也展現出顯著的增長。這些公司在當前市場動態中為未來增長奠定了良好的基礎</p>

<p>As global markets navigate the complexities of geopolitical tensions and shifting monetary policies, U.S. stocks have shown resilience with major indexes posting gains despite a hawkish Federal Reserve stance and fluctuating oil prices. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate robust earnings potential and innovation in sectors like artificial intelligence, which are poised to benefit from current market dynamics.</p>
<div class="lb-trans"><p>隨着全球市場應對地緣政治緊張局勢和貨幣政策變化的複雜性，美國股市展現出韌性，主要指數在鷹派的美聯儲立場和波動的油價背景下仍然錄得上漲。在這種情況下，識別高增長科技股需要關注那些在人工智能等領域展現出強勁盈利潛力和創新能力的公司，這些公司有望從當前市場動態中受益。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 197 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 197 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出顯示了篩選器中我們首選股票的一個子集。</p>
</div><h2>Pharming Group (ENXTAM:PHARM)</h2>
<div class="lb-trans"><h2>Pharming Group (ENXTAM:PHARM)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Pharming Group N.V. is a biopharmaceutical company that focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and internationally, with a market cap of €1.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Pharming Group N.V. 是一家生物製藥公司，專注於開發和商業化針對罕見疾病的蛋白質替代療法和精準醫療，業務覆蓋美國、歐洲及國際市場，市值為 10.1 億歐元。</p>
</div><p><strong>Operations:</strong> Pharming Group generates revenue primarily from its products Joenja® and Ruconest®, contributing $58.21 million and $317.92 million, respectively. The company is involved in the biopharmaceutical sector, focusing on rare diseases with a market cap of approximately €1 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Pharming Group 的收入主要來自其產品 Joenja® 和 Ruconest®，分別貢獻 5821 萬美元和 3.1792 億美元。該公司專注於生物製藥領域，致力於罕見疾病，市值約為 10 億歐元。</p>
</div><p>Pharming Group's recent advancements and financial growth reflect its potential in the biotech sector, particularly with its pioneering treatment, Joenja, for APDS. The company reported a significant turnaround with annual revenue rising to $376.13 million, up from $297.2 million the previous year, and transitioning from a net loss of $11.84 million to a net profit of $2.85 million. This resurgence is bolstered by strategic conference presentations and positive clinical trial outcomes that enhance its market presence in Europe and Japan. With an expected earnings growth of 36.7% per year and R&amp;D focused on addressing rare diseases through innovative treatments, Pharming is positioning itself as a key player in specialized healthcare solutions.</p>
<div class="lb-trans"><p>Pharming Group 最近的進展和財務增長反映了其在生物技術領域的潛力，特別是其針對 APDS 的開創性治療 Joenja。該公司報告顯示，年度收入從前一年的 2.972 億美元上升至 3.7613 億美元，淨虧損從 1184 萬美元轉變為淨利潤 285 萬美元。這一復甦得益於戰略性會議展示和積極的臨牀試驗結果，增強了其在歐洲和日本的市場存在。預計每年盈利增長為 36.7%，研發專注於通過創新治療解決罕見疾病，Pharming 正在將自己定位為專業醫療解決方案的關鍵參與者。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Pharming Group stock in this health report.</li>
<li>Understand Pharming Group's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Pharming Group 股票分析的全面見解，詳見此健康報告。</li>
<li>通過查看我們的歷史報告瞭解 Pharming Group 的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>ENXTAM:PHARM Revenue and Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月 ENXTAM:PHARM 收入和支出明細</p>
</div><h2>CELSYS (TSE:3663)</h2>
<div class="lb-trans"><h2>CELSYS (TSE:3663)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> CELSYS, Inc. operates in Japan providing content creation solutions and has a market cap of approximately ¥39.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CELSYS, Inc. 在日本運營，提供內容創作解決方案，市值約為 398.5 億日元。</p>
</div><p><strong>Operations:</strong> The company focuses on providing content creation solutions in Japan. It generates revenue primarily through software sales and related services, with a notable emphasis on digital illustration and animation tools.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司專注於在日本提供內容創作解決方案，主要通過軟件銷售和相關服務產生收入，特別強調數字插圖和動畫工具。</p>
</div><p>CELYS has demonstrated resilience and strategic foresight in its financial operations, particularly evident in its recent corporate actions to optimize treasury shares. With a projected annual earnings growth of 22.3% and revenue increases at 9.7% per year, the company is outpacing the Japanese market average significantly. These figures are bolstered by robust R&amp;D investments that not only underscore CELSYS's commitment to innovation but also align with broader industry trends towards enhanced digital solutions. Recent dividend adjustments reflect a tactical approach to shareholder returns, balancing between reinvestment in growth and direct shareholder value enhancement through dividends expected to rise from JPY 14.00 to JPY 20.00 per share annually.</p>
<div class="lb-trans"><p>CELSYS 在其財務運營中展現出韌性和戰略前瞻性，尤其體現在其最近的企業行動中，以優化庫藏股。預計年盈利增長為 22.3%，收入年增長率為 9.7%，顯著超過日本市場的平均水平。這些數據得益於強勁的研發投資，不僅突顯了 CELSYS 對創新的承諾，還與行業向更先進數字解決方案的趨勢相一致。最近的股息調整反映了對股東回報的戰術性方法，在增長再投資和通過預計從每股 14.00 日元提高到 20.00 日元的股息直接提升股東價值之間取得平衡。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of CELSYS.</li>
<li>Review our historical performance report to gain insights into CELSYS''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 CELSYS 的完整分析健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 CELSYS 過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月 TSE:3663 盈利和收入增長</p>
</div><h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
<div class="lb-trans"><h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Plus Alpha Consulting Co., Ltd. offers marketing and HR solutions within Japan, with a market capitalization of ¥92.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Plus Alpha Consulting Co., Ltd. 在日本提供市場營銷和人力資源解決方案，市值為 923.3 億日元。</p>
</div><p><strong>Operations:</strong> Plus Alpha Consulting Co., Ltd. generates revenue primarily through its HR solutions, which account for ¥13.84 billion, and marketing solutions, contributing ¥3.79 billion. The company operates exclusively within Japan's market, focusing on these two key segments to drive its business operations.</p>
<div class="lb-trans"><p><strong>運營：</strong> Plus Alpha Consulting Co., Ltd. 主要通過其人力資源解決方案產生收入，貢獻 138.4 億日元，以及市場營銷解決方案，貢獻 37.9 億日元。該公司專注於日本市場，致力於這兩個關鍵領域推動其業務運營。</p>
</div><p>Plus Alpha ConsultingLtd. has recently shown robust financial performance, with a notable increase in quarterly sales from JPY 3.89 billion to JPY 4.44 billion and a surge in net income from JPY 755.55 million to JPY 1.15 billion year-over-year. This growth trajectory is supported by an annual revenue growth rate of 12.5%, outpacing the Japanese market's average of 6%. The company's commitment to innovation is evident from its R&amp;D spending trends, aligning with industry shifts towards more sophisticated digital solutions and ensuring competitiveness in the evolving tech landscape.</p>
<div class="lb-trans"><p>Plus Alpha ConsultingLtd 最近展現出強勁的財務表現，季度銷售額從 38.9 億日元增加到 44.4 億日元，淨收入從 7.5555 億日元激增至 11.5 億日元，同比大幅增長。這一增長軌跡得益於 12.5% 的年收入增長率，顯著超過日本市場的平均水平 6%。該公司對創新的承諾體現在其研發支出趨勢上，與行業向更復雜數字解決方案的轉變相一致，確保在不斷發展的科技領域中的競爭力。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Plus Alpha ConsultingLtd's health report.</li>
<li>Learn about Plus Alpha ConsultingLtd's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索 Plus Alpha ConsultingLtd 健康報告中我們發現的詳細信息。</li>
<li>瞭解 Plus Alpha ConsultingLtd 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown"/></p>
<p>TSE:4071 Revenue and Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>TSE:4071 收入和支出明細截至 2026 年 5 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Click this link to deep-dive into the 197 companies within our Global High Growth Tech and AI Stocks screener.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們全球高增長科技和人工智能股票篩選器中的 197 家公司。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>使用免費的 Simply Wall St 應用程序更智能地投資，提供全球每個股票市場的詳細見解。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新警告信號或風險的提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

2026 年 5 月值得關注的高增長科技股票